{
    "clinical_study": {
        "@rank": "142890", 
        "arm_group": [
            {
                "arm_group_label": "Gastrotuss", 
                "arm_group_type": "Experimental", 
                "description": "Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.\ndosage:\nInfants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional\nInfants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
            }, 
            {
                "arm_group_label": "Thickened Formula", 
                "arm_group_type": "Active Comparator", 
                "description": "Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat."
            }, 
            {
                "arm_group_label": "control group", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The results on the efficacy of the formulations based on alginic acid are controversial.\n      Corvaglia et al demonstrated a significant reduction in reflux episodes in preterm infants\n      by evaluation with pH-impedance analysis. This study concludes that the use of alginic acid\n      reduces the acidity of the gastroesophageal reflux (GER) and has a non-systemic effect and a\n      lesser presence of side effects compared to the use of H2-receptor antagonist(H2RA) and\n      proton pump inhibitor (PPI)."
        }, 
        "brief_title": "Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate", 
        "condition": [
            "Gastroesophageal Reflux", 
            "Regurgitation", 
            "Vomiting", 
            "Chronic Cough"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastroesophageal Reflux", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary outcomes This prospective, randomized, controlled trial aims to determine, in a\n      population of infants within one year of life, suffering from gastroesophageal reflux (GER)\n      the effectiveness of magnesium alginate. The clinical improvement of the patient will be\n      evaluated based on the negativity of the symptom score (4.3.1), assessed using a validated\n      questionnaire on symptoms of GER (I-GERQ Annex A).\n\n      Secondary outcomes To compare the efficacy of Magnesium Alginate on GER in infants compared\n      with those of thickened feeding and reassurance, basing on questionnaire results."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age < 1 year\n\n          -  Suggestive symptoms of gastroesophageal reflux (I-GERQ score > 7)\n\n          -  Absence of clinical evidence of allergy to cow milk protein or other allergic\n             disorder\n\n          -  No previous intake of thickened formulas, acid suppressants or drugs\n\n          -  All parents or guardians must sign a document of informed consent\n\n          -  Patients affected by chronic disease\n\n          -  Patients affected by hepatic or renal diseases\n\n          -  Patients affected by cardiac diseases\n\n        Exclusion Criteria:\n\n          -  Patients affected by chronic disease\n\n          -  Patients affected by hepatic or renal diseases\n\n          -  Patients affected by cardiac diseases\n\n          -  Inability or unwillingness to give informed consent\n\n          -  Patients wth severe neurologic disease\n\n          -  Patients affected by cow milk protein allergy\n\n          -  Previous or ongoing intake of thickened formulas, acid suppressants or drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858584", 
            "org_study_id": "STDMG2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gastrotuss", 
                "description": "Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.\ndosage:\nInfants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional\nInfants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day", 
                "intervention_name": "Gastrotuss", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Thickened Formula", 
                "description": "Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.", 
                "intervention_name": "thickened milk", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Alginic acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GER", 
            "Alginate", 
            "Regurgitation", 
            "questionnaire"
        ], 
        "lastchanged_date": "May 29, 2013", 
        "location": {
            "contact": {
                "email": "dariummarino@virgilio.it", 
                "last_name": "Dario Ummarino", 
                "phone": "348 5481267"
            }, 
            "facility": {
                "address": {
                    "city": "Naples", 
                    "country": "Italy", 
                    "zip": "80131"
                }, 
                "name": "university of Naples Federico II"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate", 
        "overall_contact": {
            "email": "staiano@unina.it", 
            "last_name": "Annamaria Staiano", 
            "phone": "+39 081 7462669"
        }, 
        "overall_official": {
            "affiliation": "Federico II University", 
            "last_name": "Annamaria Staiano", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee of the University of Naples Federico II", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This prospective, randomized, controlled trial aims to determine, in a population of infants within one year of life, suffering from RGE the effectiveness of magnesium alginate. The clinical improvement of the patient will be evaluated based on the negativity of the symptom score (4.3.1), assessed using a validated questionnaire on symptoms of GER (I-GERQ Annex A).", 
            "measure": "efficacy on GER", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858584"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federico II University", 
            "investigator_full_name": "Dario Ummarino", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "\u2022\tTo compare the efficacy of Magnesium Alginate on GER in infants compared with those of thickened feeding and reassurance.", 
            "measure": "comparison of treatments", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "source": "Federico II University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federico II University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}